ASDR 2025 Gold Sponsor
Boehringer Ingelheim
Boehringer Ingelheim is a research-driven biopharmaceutical company targeting areas of high unmet medical need to improve and extend the lives of humans and animals. Family-owned since 1885, we are among the top 20 companies in the industry. Our innovations transform the lives of over a million Australians living with cardio-renal-metabolic and respiratory diseases, and our rich R&D pipeline is targeting breakthroughs in these and other areas including cancer and mental health. The company invested 5.0 billion euros into R&D worldwide in 2022, including millions into local Australian clinical trials, to create breakthrough therapies that address healthcare's greatest challenges.
